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Abstract
Purpose—Uptake and completion of the 3-dose human papillomavirus (HPV) vaccine is 
important for the primary prevention of cervical cancer. However, HPV vaccination rates among 
adolescent females and young women remain low in certain geographic areas of the United States, 
including Appalachia. Although greater fatalistic beliefs have been previously associated with 
lower rates of preventive cancer behaviors among adults, little research exists on the impact of 
fatalism on HPV vaccination behaviors, especially among younger individuals. Therefore, the 
purpose of this study was to examine the association between fatalistic beliefs and completion of 
the full HPV vaccine series among young women, ages 18–26, in Appalachian Kentucky.
Results—Data from this study were from a baseline survey completed by 344 women 
randomized into a communication intervention trial focused on increasing adherence to the 3-dose 
HPV vaccine series. Principal components analysis was used to construct 2 fatalism-related 
subscales from 8 survey questions.
Findings—In a controlled analysis, 1 subscale—“lack of control over cancer”— was 
significantly associated with not completing the full HPV vaccine series. In a rural area that 
experiences higher rates of cervical cancer, poverty, limited access to health care, and negative 
cancer-related attitudes and experiences, fatalism may be common, even among young people.
Conclusion—Future educational and interventional research addressing fatalistic beliefs in a 
culturally sensitive manner may be warranted to improve HPV vaccination behaviors and impact 
cancer disparities among Appalachian women.
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Human papillomavirus (HPV) is the most prevalent sexually transmitted infection in the 
United States, affecting an estimated 79 million individuals.1 High-risk HPV types are 
associated with various cancers, with HPV types 16 and 18 causing an estimated two-thirds 
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of all cervical cancers.1 Two vaccines (HPV4, Gardasil®; HPV2, Cervarix®) are now widely 
available for the primary prevention of HPV infection and cervical cancer.2 The Centers for 
Disease Control and Prevention (CDC) recommends routine HPV vaccination for females 
ages 11–12 and catch-up vaccination for females ages 13–26. Current CDC guidelines 
recommend that the second dose of the HPV vaccine series be administed 1–2 months after 
the first injection; the third dose is administered 6 months after the first dose.3 
Unfortunately, HPV vaccination rates remain below Healthy People 2020 targets, especially 
among young adult women and in regions of the country that may need this cancer 
prevention strategy the most, including Appalachia.4–6 Lower HPV vaccination rates in 
Appalachia are problematic considering the higher prevalence of high-risk HPV infection 
and cervical cancer incidence and mortality rates in that region.7–11
Barriers to the initial uptake and eventual completion of the 3-dose HPV vaccine series 
among Appalachian women have been previously documented, with the high monetary cost 
of vaccination serving as a primary barrier.12–14 However, Crosby et al found that even 
when the barrier of cost was removed, young women residing in rural Appalachian 
Kentucky were less likely than their urban counterparts to accept and complete HPV 
vaccination.5 This finding suggests that factors unrelated to cost may serve as important 
barriers to HPV vaccination behaviors. Other noted barriers to HPV vaccination among 
Appalachian women include lack of transportation, limited parental/peer/health care 
provider support, cultural views, and lack of knowledge regarding cervical cancer 
prevention and HPV.13,15–17
There is an additional barrier to preventive cancer behavior, however, that has received 
limited attention as it relates to HPV vaccination, and that is the concept of fatalism. 
Fatalism has been examined as a potential determinant for engaging in preventive cancer 
strategies, including cancer information seeking, screening (eg, colorectal cancer screening, 
Papanicolaou [Pap] testing, mammography) and preventive behaviors (eg, diet, exercise, 
smoking).18–22 Although the definition of fatalism varies across studies and disciplines, the 
concept is often operationalized as mortality from cancer being inevitable and that the 
disease is beyond an individual’s personal control.19,23–25 Indeed, fatalistic beliefs have 
been previously identified as barriers to cancer prevention and screening among racial/ethnic 
minorities, individuals of lower socioeconomic status, the elderly, rural populations, and 
Appalachians.23,25–33 However, there has been limited research on the potential impact of 
fatalistic beliefs on HPV vaccination behaviors as a preventive cancer strategy, specifically 
among young Appalachian adults.13,34 Therefore, the purpose of this study was to examine 
whether fatalistic beliefs were associated with completion of the full HPV vaccine series 
among young women in Appalachian Kentucky.
Methods
Study Participants
This study used baseline data from a health communication intervention trial conducted in 
2010–2011, which focused on promoting uptake and adherence to the HPV vaccine among 
women aged 18–26 in an 8-county region of Appalachian Kentucky.35 The study catchment 
area is extremely rural; the 8 counties are assigned a 2013 Rural-Urban Continuum Code of 
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either 7 or 9 as defined by the US Department of Agriculture’s Economic Research 
Service.36 A convenience sample of eligible women was recruited through a community-
based social marketing campaign, which advertised the availability of free HPV vaccination 
for women in the appropriate age range. Dose 1 of the HPV vaccine (HPV4) was provided at 
no cost by research nurses at local health departments and other health care settings, 
community colleges, supermarkets, community gatherings (eg, fall festivals), and in 
women’s homes.
Procedures
After dose 1 of the vaccine was given, women were asked to participate in a research study; 
all volunteers provided written informed consent. After consent was obtained, women were 
asked to complete a baseline questionnaire via audio computer-assisted self-interviewing. 
The purpose of the survey was to identify predictors of intent to complete the HPV vaccine 
series as well as predictors of actual series completion. Survey questions were informed by 
constructs from the Theory of Planned Behavior as well as previous research findings.5,37–39 
After completing the questionnaire, women were subsequently randomized into an 
intervention or comparison group. Women in the intervention group viewed a 13-minute 
educational DVD, called “1–2–3 Pap,” while women in the comparison group received a 
standard-of-care pamphlet regarding HPV vaccination. The “1–2–3 Pap” DVD focused on 
the importance of HPV vaccination and guideline-concordant Pap testing for Appalachian 
Kentucky women. Messaging for the DVD was based on formative research conducted by 
Head et al and guided by the information, motivation, behavioral skills model.14 The DVD 
included several key thematic messages, including the prevalence of HPV, the burden of 
cervical cancer in eastern Kentucky, the effectiveness of the HPV vaccine, and the 
recommended vaccination schedule. All women received reminder telephone calls for doses 
2 and 3. Data on women’s vaccine series completion were taken from medical records and 
reviewed for up to 9 months past the date of series initiation. Results of the intervention trial 
are published elsewhere.35 The University of Kentucky Institutional Review Board 
approved all research activities.
Measures
Fatalistic beliefs were assessed on the baseline survey via 8 questions measured on a 5-point 
Likert scale (Strongly Agree, Agree, Unsure, Disagree, Strongly Disagree). These questions 
were informed by a review of the literature, and the research expertise and field-based 
experiences of the investigators.18,24,40
Data Analyses
For the purposes of this study, demographic and clinical variables, as well as HPV vaccine 
efficacy beliefs, intention to complete the HPV vaccine series, and barriers to vaccination 
were first tested to determine equivalence between the intervention and comparison groups. 
Independent samples t tests were used to test continuous-level variables. Fisher’s exact tests 
were used to test all dichotomous-level variables. Responses to the fatalism questions were 
dichotomized into Agree (Strongly Agree, Agree) or Disagree (Unsure, Disagree, Strongly 
Disagree). To identify potential subscales within these 8 questions, a principal components 
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analysis was conducted.41,42 Subscales were identified, constructed, and tested for interitem 
reliability. Multivariate logistic regression models were created in order to assess the 
possible associations between HPV vaccine series noncompletion and fatalistic scales 
categorized as fatalistic or nonfatalistic/ unsure. Models used backwards entry, initially 
controlling for all demographic, clinical, HPV vaccine efficacy beliefs, intention, and 
barrier-related variables listed in Table 1. Statistical significance was determined at P ≤ .05. 
All data analyses were conducted using SAS Version 9.3 for Windows (SAS Institute Inc., 
Cary, North Carolina).
Results
During the study, 344 women received dose 1 of the HPV vaccine and completed the 
baseline survey prior to randomization into the intervention trial. Overall, the mean age was 
22 years (SD = 2.4); the study sample primarily comprised non-Hispanic white females 
(94.0%). Almost all of the women (90%) had lived in southeastern Kentucky for over 5 
years. Only one-quarter (25.6%) were employed full-time; almost half (48.0%) reported 
some college as their highest level of education. Nearly one-third (30%) of the women were 
married and 39.0% reported having children at home. As shown in Table 1, there were 
statistically significant between-group differences in age, history of an abnormal Pap test, 
the belief that all 3 doses of the HPV vaccine will decrease the chance of developing 
cervical cancer, intention to complete the entire vaccine series, and transportation barriers 
between comparison groups, and therefore adjustments were made in all subsequent models.
Responses to the 8 fatalism questions were subjected to a principal component analysis. The 
principal axis method was used to extract the components, followed by a varimax 
(orthogonal) rotation. Only the first 2 components displayed eigenvalues greater than 1, and 
the results of a screen test also suggested that only the first 2 components were meaningful. 
Therefore, only the first 2 components were retained for rotation. Combined, components 1 
and 2 accounted for 52.03% of the total variance. Questionnaire items and corresponding 
factor loadings are presented in Table 2. In interpreting the rotated factor pattern, an item 
was said to load on a given component if the factor loading was .40 or greater for that 
component, and it was less than .40 for the other. Using these criteria, 5 items were found to 
load on the first component, which was subsequently labeled the “inevitability of cancer” 
component. Three items loaded on the second component, which was labeled the “lack of 
control over cancer” component.
We tested 3 scales for these fatalistic questions: (1) a total scale summed over all 8 
questions, (2) a summed subscale over the 5 questions representing the “inevitability of 
cancer,” and (3) a summed subscale over the 3 questions representing the “lack of control 
over cancer.” We then categorized these 3 scales into fatalistic (>scale midpoint) or not 
fatalistic/unsure (≤scale midpoint). Table 3 displays the raw scores and ranges for all women 
as well as the percent categorized as fatalistic or not-fatalistic/unsure. The first adjusted 
model, utilizing the total fatalism score and controlling for randomization, vaccine efficacy 
beliefs, intention to complete series, and transportation barriers, showed that women who 
answered fatalistically had no statistically significant difference in the odds of not 
completing the entire series as compared to those that were not fatalistic or unsure (OR = 
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1.53; 95% CI: 0.86–2.70; P = .15; data not shown). We then constructed a logistic model 
incorporating the 2 created fatalism subscales (Table 4). In this model, the “inevitability of 
cancer” scale was not significant; however, women scoring above the midpoint on the “lack 
of control over cancer” scale had 2.44 times the odds of not completing the full dose series 
as compared to those scoring below the midpoint (95% CI: 1.34–4.45; P = .004). As 
reported elsewhere, the DVD intervention was significantly associated with higher rates of 
HPV vaccine series completion (OR = 2.72; 95% CI: 1.59–4.65; P < .001), and intention to 
not complete the vaccine series also increased the risk of not completing the full regimen 
(OR = 2.12; 95% CI: 1.13–4.00; P = .020).35 In addition, women indicating that 
transportation would be an issue to returning for subsequent vaccinations had significantly 
higher odds of not completing the series (OR = 3.81; 95% CI: 1.84–7.91; P < .001).
Discussion
Among this sample of young Appalachian Kentucky women, ages 18–26, who received at 
least dose 1 of the HPV vaccine, several fatalistic beliefs resulted in a higher likelihood of 
not successfully completing the full HPV vaccine series. Specifically, women indicating 
agreement with the 3 beliefs related to limited control over their health (generally) and 
cervical cancer (specifically) were significantly less likely to complete the series. Although 
the inevitability of cancer scale was not significant, several of the included fatalistic beliefs 
have been previously found among rural and Appalachian populations, specifically those 
beliefs pertaining to the inevitability of developing cancer due to familial history, the 
perception that cancer is unavoidable, and that cancer is a death sentence.43–46 Notably, this 
is the first study to measure the impact of fatalism on HPV vaccination outcomes among a 
younger population of Appalachian women. Katz et al reported that fatalism could be a 
perceived barrier to HPV vaccination acceptability among Appalachian Ohio residents, but 
this finding was a result of qualitative focus groups and interviews with health care 
providers, parents, young women, and community members. Furthermore, only 1 fatalistic 
belief, specifically fear of cancer, was described in that study.13
Importantly, all of the women in the study received dose 1 of the HPV vaccine, regardless of 
their fatalistic beliefs. However, similar to Vanderpool et al, our findings suggest there may 
be different barriers to HPV vaccine series completion as compared to barriers associated 
with initial vaccine uptake.35 In this case, having negative perceptions related to the control 
of cancer was associated with not completing the full HPV vaccine series. This is an 
important finding because rural Appalachian residents often perceive cancer as pervasive, 
inevitable, and mostly hereditary.45,46 For example, participants’ perceived lack of control 
over cancer may be related to cultural practices of storytelling, wherein family, friends, and 
community members’ negative experiences with the disease are perpetuated over time. 
Because of the small, tightknit nature of these rural communities, an individual’s cancer 
experience—and the associated anxiety, fear, and consequences—is projected onto family 
members, their broader peer group, and the community as a whole.45 As a result, individuals 
may forgo preventive behaviors as a way to avoid or deny the health issue altogether, 
particularly if they believe their personal risk is elevated.47 Appalachian residents may also 
exhibit lower self-efficacy in regards to controlling cancer due to multiple ecological 
barriers, including limited access to health care, lower socioeconomic status, poorer health 
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status, and poor patient-provider communication.12,13,33,46 These circumstances, in the 
context of a high-poverty region with limited resources such as Appalachia, may lead to 
fatalistic beliefs, including those identified in this study. Thus, fatalism, negative attitudes 
toward health, and health care avoidance may be more commonplace in rural Appalachia, 
even among young people.25,44,48
There are noted limitations to our study, including the design of our baseline survey, which 
did not allow for measuring changes in fatalistic beliefs over time, and the limited 
generalizability of our findings to other rural and/or Appalachian populations. In addition, 
this study focused on women who had already initiated the HPV vaccine series; fatalistic 
beliefs among women who have chosen to initiate the HPV vaccine series may differ from 
those who have not initiated the series. Therefore, our findings may not be generalizable to 
women who have yet to receive dose 1. In addition, we recognized the moderate Cronbach 
alpha coefficients for the 3 fatalism scales.
Conclusions
As suggested by the study findings, we identified a potentially modifiable determinant of 
HPV vaccine series noncompletion among a group of women living in a region of the 
country which experiences an undue burden of cervical cancer and low HPV vaccination 
rates. Indeed, the efficacy of the HPV vaccine is based on the completion of the entire 
series; thus, identifying and intervening on individual-level barriers to vaccine series 
completion is necessary to improve HPV vaccination rates among young women.2 For 
example, inclusion of fatalism-related questions on patient screening forms could be used to 
proactively identify women at risk of failing to complete the HPV vaccine series and 
intensify patient tracking and reminder systems. As previously mentioned, fatalistic beliefs 
among women who have initiated the HPV vaccine series may differ from those who have 
not. Further research efforts should compare fatalistic beliefs between these 2 groups of 
women. Additional tailored communication messages may also be needed to educate and 
empower Appalachian women to participate in evidence-based cervical cancer prevention 
and screening strategies. In sum, future educational and interventional research which 
addresses fatalistic beliefs in a culturally sensitive manner may be warranted to improve 
HPV vaccination rates and impact cancer disparities among women in Appalachia.
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Table 1
Sample Characteristics (N = 344)
DVD Intervention
(N = 178)
Control Group
(N = 166) P*
n (%) n (%)
Demographic
Age, mean (SD) 22.2 (2.5) 21.7 (2.3) .05
Highest level of education completed .53
  Less than high school 15 (8.4) 9 (5.4)
  High school graduate 55 (30.9) 51 (30.7)
  More than high school 108 (60.7) 106 (63.9)
Clinical
Ever had an abnormal Pap test result? .05
  Yes 72 (44.4) 79 (51.6)
  No 90 (55.6) 74 (48.4)
Ever been diagnosed with an STI? .22
  Yes 39 (21.9) 36 (21.7)
  No 139 (78.1) 130 (78.3)
Vaccine intention/efficacy beliefs/barriers
Intend to complete the 3-dose HPV vaccine series .02
  Yes 103 (58.2) 117 (70.9)
  No 74 (41.8) 48 (29.1)
Three doses of the HPV vaccine will decrease my cervical cancer risk .03
  Unsure/Agree/Strongly Agree 120 (67.4) 130 (78.3)
  Disagree/Strongly Disagree 58 (32.6) 36 (21.7)
Would return for doses 2 and 3 if friend came with me .22
  Unsure/Agree/Strongly Agree 62 (34.8) 69 (41.6)
  Disagree/Strongly Disagree 116 (65.2) 97 (58.4)
Transportation issues would prevent return for doses 2 and 3 .02
  Yes 50 (28.3) 29 (17.6)
  No 127 (71.7) 136 (82.4)
Work schedule would prevent return for doses 2 and 3 .73
  Yes 56 (31.6) 49 (46.7)
  No 121 (68.4) 116 (70.3)
SD = standard deviation; STI = sexually transmitted infection.
*
P values from independent samples t test or Fisher’s exact tests.
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Table 2
Rotated Factor Pattern and Final Communality Estimates From Principal Components Analysis of Fatalistic 
Questions
Component
1 2 h2 a
1. Cancer of the cervix is beyond my control .34 .66 0.55
2. Cancer of any kind is a death sentence .76 −.11 0.58
3. Cancer of the cervix is almost always fatal .64 .12 0.42
4. Cancer is a disease that cannot be avoided .63 .27 0.47
5. If it were fated for me to get cervical cancer getting vaccinated against HPV would not prevent it .11 .83 0.70
6. Women in my family get cervical cancer so I will probably get it also .69 −.12 0.49
7. Faith is all I need to prevent diseases and illness .48 .31 0.32
8. I am not in control of my own health −.27 .75 0.63
aN = 344. Communality estimates appear in column headed h2.
“Inevitability of cancer” = Questions 2, 3, 4, 6, 7.
“Lack of control over cancer” = Questions 1, 5, 8.
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Table 4
Multivariate Associations Among HPV Vaccine Series Noncompletion and Fatalism
Odds of Series Noncompletion (95% CI) P*
Inevitability of cancer scale 0.94 (0.51–1.76) .854
Lack of control over cancer scale 2.44 (1.24–4.45) .004
Transportation issues would prevent return 3.81 (1.84–7.91) <.001
Did not receive the DVD intervention 2.72 (1.59–4.65) <.001
Did not intend to complete the series 2.12 (1.13–4.00) .020
*
P values from multivariate logistic regression modeling the probability of series dose noncompletion. Model chosen using backwards selection 
from covariates described in the text.
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